Version number: 14



SAFETY DATA SHEET

1. Identification

Product identifier LISKONUM TABLETS

Other means of identification

Synonyms LISKONUM CONTROLLED RELEASE TABLETS 450 MG * ESKALITH CONTROLLED RELEASE

TABLETS 450 MG * QUILONUM SR TABLETS * QUILONUM 450 MG SR TABLETS * QUILONIUM-R TABLETS * LITHIUM CARBONATE, FORMULATED PRODUCT

Recommended use of the chemical and restrictions on use

Medicinal Product. Recommended use

> This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant

to medicinal use of the product. In this instance patients should consult prescribing

information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate

safety data sheet for each ingredient.

Restrictions on use No other uses are advised.

Details of manufacturer or importer

Manufacturer

GlaxoSmithKline Australia 1061 Mountain Highway Melbourne, Victoria 3155

Australia General Information (Normal Business Hours): (03) 9721 6000

TRANSPORTATION EMERGENCY NUMBERS (available 24hrs/7days: multi-language response)

Australia Toll Free +(61) 2 9037 2994 International Toll Call +(1) 703 527 3887

2. Hazard(s) identification

Classification of the hazardous chemical

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Label elements, including precautionary statements

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

Other hazards which do not result in classification

Exempt from requirements - product regulated as a medicinal product, cosmetic product or medical device.

3. Composition/information on ingredients

Mixture

Identity of chemical ingredients	CAS number and other unique identifiers	Concentration of ingredients
LITHIUM CARBONATE	554-13-2	< 65
Carbonic acid, dilithium salt DILITHIUM CARBONATE CARBONIC ACID, LITHIUM SALT		
POVIDONE 30	9003-39-8	< 15
Poly(1-ethenylpyrrolid-2-one) CROSPOVIDONE POLY(1-VINYL-2-PYRROLIDINONE) 2-PYRROLIDINONE, 1-VINYL-, POLYMERS		

Material name: LISKONUM TABLETS

SDS AUSTRALIA

Talc	14807-96-6	< 10	
TALCUM, NON-ASBESTOS FORM Talc HYDROUS MAGNESIUM SILICATE			
Titanium dioxide	13463-67-7	< 0.25	
TITANIUM OXIDE TITANIUM(IV) OXIDE TITANIUM PEROXIDE (TIO2) PIGMENT WHITE 6			
Other components below reportable levels		< 20	

4. First-aid measures

Description of necessary first aid measures

Inhalation Move to fresh air. If breathing is difficult, trained personnel should give oxygen. Call a physician if

symptoms develop or persist. Under normal conditions of intended use, this material is not

expected to be an inhalation hazard.

Skin contact Immediately flush skin with plenty of water. Take off contaminated clothing and wash before reuse.

Get medical attention if symptoms occur.

Eye contact Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.

Ingestion If swallowed, rinse mouth with water (only if the person is conscious). If ingestion of a large

amount does occur, call a poison control centre immediately. Do not induce vomiting without

advice from poison control center.

Personal protection for first-aid

responders

In the case of accident or if you feel unwell, seek medical advice immediately (show the label where possible). Ensure that medical personnel are aware of the material(s) involved, and take precautions to protect themselves.

Symptoms caused by exposure

Direct contact with eyes may cause temporary irritation. Symptoms may include stinging, tearing, redness, swelling, and blurred vision. The following adverse effects have been noted with therapeutic use of this material: anorexia; dry mouth; nausea; vomiting; diarrhoea; tremor; thirst;

mental impairment.

Medical attention and special

treatment

No specific antidotes are recommended. Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control

information centre.

5. Fire-fighting measures

Extinguishing media

Suitable extinguishing

media

Water. Foam. Dry chemical powder. Carbon dioxide (CO2).

Unsuitable extinguishing

media

None known.

Specific hazards arising from

the chemical

During fire, gases hazardous to health may be formed.

Special protective equipment and precautions for fire

fighters

Self-contained breathing apparatus and full protective clothing must be worn in case of fire.

Fire fighting

equipment/instructions

Move containers from fire area if you can do so without risk.

Not available. **Hazchem Code**

General fire hazards No unusual fire or explosion hazards noted.

Specific methods Use standard firefighting procedures and consider the hazards of other involved materials.

6. Accidental release measures

Personal precautions, protective equipment and emergency procedures

For non-emergency

personnel

Keep unnecessary personnel away. Keep people away from and upwind of spill/leak. Keep out of low areas. Wear appropriate protective equipment and clothing during clean-up. Do not touch damaged containers or spilled material unless wearing appropriate protective clothing. Ensure adequate ventilation. Local authorities should be advised if significant spillages cannot be

contained. For personal protection, see section 8.

Keep unnecessary personnel away. Use personal protection recommended in Section 8 of the For emergency responders

SDS.

Material name: LISKONUM TABLETS

SDS AUSTRALIA

Environmental precautions

Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Avoid discharge into drains, water courses or onto the ground. Inform appropriate managerial or supervisory personnel of all environmental releases.

Methods and materials for containment and cleaning up Stop the flow of material, if this is without risk. Prevent entry into waterways, sewer, basements or confined areas. Following product recovery, flush area with water. For waste disposal, see section 13 of the SDS.

7. Handling and storage

Precautions for safe handling

Obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Avoid contact with eyes. Avoid prolonged exposure. Do not taste or swallow. When using, do not eat, drink or smoke. Pregnant or breastfeeding women must not handle this product. Should be handled in closed systems, if possible. Provide adequate ventilation. Wear appropriate personal protective equipment. Wash hands thoroughly after handling. Avoid release to the environment. Observe good industrial hygiene practices.

Conditions for safe storage, including any incompatibilities Store locked up. Store in original tightly closed container. Store away from incompatible materials (see Section 10 of the SDS).

8. Exposure controls and personal protection

Control parameters

Follow standard monitoring procedures.

Occupational exposure limits

GS	K

Components	Туре	Value	Note
LITHIUM CARBONATE (CAS 554-13-2)	8 HR TWA	400 mcg/m3	
,	OHC	2	Reproductive hazard
Australia. National Workpla	ce OELs (Workplace Exposure Standa	ards for Airborne Contamin	ants, Appendix A)
Components	Туре	Value	Form
Talc (CAS 14807-96-6)	TWA	2.5 mg/m3	
Titanium dioxide (CAS 13463-67-7)	TWA	10 mg/m3	Inhalable dust.
Australia. OELs. (Adopted Invironment)	National Exposure Standards for Atmo	ospheric Contaminants in th	ne Occupational
Components	Туре	Value	Form
Talc (CAS 14807-96-6)	TWA	2.5 mg/m3	
Titanium dioxide (CAS 13463-67-7)	TWA	10 mg/m3	Inspirable dust.
US. ACGIH Threshold Limit	Values		
Components	Туре	Value	Form
Talc (CAS 14807-96-6)	TWA	2 mg/m3	Respirable fraction.
Titanium dioxide (CAS 13463-67-7)	TWA	10 mg/m3	
UK. EH40 Workplace Expos	sure Limits (WELs)		
Components	Type	Value	Form
Talc (CAS 14807-96-6)	TWA	1 mg/m3	Respirable dust.
Titanium dioxide (CAS 13463-67-7)	TWA	4 mg/m3	Respirable.
•		10 mg/m3	Inhalable
logical limit values	No biological exposure limits noted for	the ingredient(s).	
osure guidelines			
propriate engineering	An Exposure Control Approach (ECA)		

controls

upon the OEL/Occupational Hazard Category and the outcome of a site- or operation-specific risk assessment. General ventilation normally adequate.

Individual protection measures, for example personal protective equipment (PPE)

Eye/face protection If contact is likely, safety glasses with side shields are recommended.

Skin protection

Hand protection For prolonged or repeated skin contact use suitable protective gloves.

Other Wear suitable protective clothing as protection against splashing or contamination.

Material name: LISKONUM TABLETS

Respiratory protection When workers are facing concentrations above the exposure limit they must use appropriate

certified respirators.

Thermal hazards Wear appropriate thermal protective clothing, when necessary.

Hygiene measures Always observe good personal hygiene measures, such as washing after handling the material

and before eating, drinking, and/or smoking. Routinely wash work clothing and protective equipment to remove contaminants. For advice on suitable monitoring methods, seek guidance

from a qualified environment, health and safety professional.

9. Physical and chemical properties

Appearance

Solid. Physical state **Form** Tablet.

Colour Not available. Not available. Odour **Odour threshold** Not available. pН Not available. Not available. Melting point/freezing point Initial boiling point and boiling Not available.

range

Not available. Flash point **Evaporation rate** Not available. Flammability (solid, gas) Not available. Upper/lower flammability or explosive limits

Flammability limit - lower

Not available.

(%)

Flammability limit - upper

Not available.

Explosive limit - lower (%) Not available. Not available. Explosive limit - upper

(%)

Not available. Vapour pressure Not available. Vapour density Not available. Relative density

Solubility(ies)

Solubility (water) Not available. Partition coefficient Not available.

(n-octanol/water)

Not available. **Auto-ignition temperature** Not available. **Decomposition temperature** Not available. **Viscosity**

10. Stability and reactivity

The product is stable and non-reactive under normal conditions of use, storage and transport. Reactivity

Chemical stability Material is stable under normal conditions.

Possibility of hazardous

reactions

No dangerous reaction known under conditions of normal use.

Conditions to avoid Contact with incompatible materials.

Incompatible materials Peroxides. Phenols.

Hazardous decomposition

products

None known. Irritating and/or toxic fumes and gases may be emitted upon the product's

decomposition.

11. Toxicological information

Information on possible routes of exposure

Inhalation Under normal conditions of intended use, this material is not expected to be an inhalation hazard. **Skin contact** Health injuries are not known or expected under normal use.

Eye contact Health injuries are not known or expected under normal use. Direct contact with eyes may cause

temporary irritation.

Ingestion Health injuries are not known or expected under normal use. Harmful if swallowed. However,

ingestion is not likely to be a primary route of occupational exposure.

Symptoms related to exposure Direct contact with eyes may cause temporary irritation. Exposed may experience eye tearing,

redness, and discomfort.

The following adverse effects have been noted with therapeutic use of this material: anorexia; dry

mouth; nausea; vomiting; diarrhoea; tremor; thirst; mental impairment.

Acute toxicity Harmful if swallowed. Expected to be a low hazard for usual industrial or commercial handling by

trained personnel.

Components **Species Test results** LITHIUM CARBONATE (CAS 554-13-2) Acute Inhalation Human >= 1 mg/m3 Respiratory irritation Oral LD50 Rat 600 mg/kg POVIDONE 30 (CAS 9003-39-8) **Acute** Oral LD50 Rat > 5000 mg/kg Titanium dioxide (CAS 13463-67-7) Acute Inhalation LC50 Rat 6820 mcg/m3 Oral LD50 Rat > 24 g/kg Chronic Inhalation LOEC Rat 8.6 mg/m3, 1 years TiO2 accumulated in interstitial macrophages, aggregated interstitial cells and particle laden macrophrages in lymphoid tissue. NOAEC Rat 250 mg/m3, 2 years Highest dose 5 mg/m3, 24 months **Subacute** Inhalation LOEL Rat 0.1 - 35 mg/m3, 4 weeks Mild macrophage hyperplasia, no change in bronchio-alveolar lavage fluid. NOAEC Guinea pig 26 mg/m3, 3 weeks No evidence of significant inflammation in respiratory tract. Oral NOAEL Rat 100000 ppm, 14 Day Dietary study, highest dose tested. **Subchronic** Inhalation LOEC Rat 3.2 - 20 mg/m3, 8 min Accumulation of TiO2 in macrophages and evidence of pulmonary inflammation.

Skin corrosion/irritation Health injuries are not known or expected under normal use.

Material name: LISKONUM TABLETS

^{*} Estimates for product may be based on additional component data not shown.

Irritation Corrosion - Skin

TITANIUM DIOXIDE 0, Literature data Result: Non-irritant

Species: Guinea pig 0. Literature data Result: Non-irritant Species: Human

Acute dermal irritation; OECD 404, Literature data

Result: Non-irritant Species: Rabbit

Serious eye damage/irritation

Health injuries are not known or expected under normal use. Direct contact with eyes may cause

temporary irritation.

Eye

LITHIUM CARBONATE **OECD 405**

Result: Irritant Species: Rabbit

Notes: Literature Reference TITANIUM DIOXIDE OECD 405, Literature data

Result: Mild irritant Species: Rabbit

Respiratory or skin sensitisation

Respiratory sensitisation None known.

Skin sensitisation None known. This product is not expected to cause skin sensitisation.

Sensitisation

TITANIUM DIOXIDE 5 % Optimisation Test, Literature data - Vehicle: petrolatum

> Result: negative Species: Guinea pig

Test Duration: 48 hour exposure Patch test, Literature data

Result: negative Species: Human

Germ cell mutagenicity

No data available to indicate product or any components present at greater than 0.1% are

mutagenic or genotoxic.

Mutagenicity

TITANIUM DIOXIDE Ames, Literature data

Result: negative

Micronucleus Assay in vitro, CHO cells, Literature data

Result: negative

Micronucleus Assay in vitro, cultured human peripheral

lymphocytes, Literature data

Result: positive

Syrian Hamster Embryo (SHE) cell transformation assay

Result: negative

WIL2-NS HPRT/ t-Thioguanidine - Human B-Cell

lymphoblastoid, Literature data

Not classifiable as to carcinogenicity to humans. Carcinogenic effects are not expected as a result

Result: positive

LITHIUM CARBONATE

Carcinogenicity

of occupational exposure.

Species: Rat

TITANIUM DIOXIDE

0.02 mmol/L, NOAEL

Notes: Literature Reference

0.5 mg/m3, Literature data

Result: negative Species: Rat

Test Duration: 24 months

0.72 - 14.8 mg/m3, Literature data

Result: negative Species: Mouse

10 - 250 mg/m3, Dietary study - Literature data.

Result: Inflammation at all doses with alveolar/bronchiolar

SDS AUSTRALIA

adenoma at the highest concentration.

Species: Rat

Test Duration: 24 months

Material name: LISKONUM TABLETS 4365

6 / 10

Carcinogenicity

TITANIUM DIOXIDE 25000 - 50000 ppm, Dietary study

Result: negative Species: Mouse

25000 - 50000 ppm, Dietary study - Literature data.

Result: negative Species: Rat

7.2 - 14.8 mg/m3, Literature data

Result: Lung tumour Species: Rat

Test Duration: 24 months

ACGIH Carcinogens

Talc (CAS 14807-96-6) A4 Not classifiable as a human carcinogen. Titanium dioxide (CAS 13463-67-7) A4 Not classifiable as a human carcinogen.

IARC Monographs. Overall Evaluation of Carcinogenicity

POVIDONE 30 (CAS 9003-39-8) 3 Not classifiable as to carcinogenicity to humans.

Titanium dioxide (CAS 13463-67-7) 2B Possibly carcinogenic to humans.

Components in this product have been shown to cause birth defects and reproductive disorders in Reproductive toxicity

laboratory animals. These effects are linked only to high doses of this substance; low doses did

not produce this adverse effect.

Specific target organ toxicity -

single exposure

Central nervous system.

LITHIUM CARBONATE Organ: Central nervous system.

Notes: Literature Reference

Specific target organ toxicity -

repeated exposure

Kidneys.

LITHIUM CARBONATE

Notes: Literature Reference

Organ: Kidney

Not likely, due to the form of the product. **Aspiration hazard**

Chronic effects Prolonged exposure may cause chronic effects.

Caution - Pharmaceutical agent. Occupational exposure to the substance or mixture may cause Other information

adverse effects.

12. Ecological information

Ecotoxicity Not expected to be harmful to aquatic organisms.

Components		Species	Test results
LITHIUM CARBONATE (CA	AS 554-13-2)		
Aquatic			
Acute			
Crustacea	EC50	Water flea (Daphnia magna)	1.2 mg/l, 48 hours Static test
Fish	EC50	Rainbow trout (Adult Oncorhyncus mykiss)	9.3 mg/l, 28 days Static renewal test
POVIDONE 30 (CAS 9003-	39-8)		
Acute			
	IC50	Activated sludge	> 1000 mg/l, 3 hours Static test
Aquatic			
Acute			
Crustacea	EC50	Water flea (Daphnia magna)	84 mg/l, 48 hours Static test
	NOEC	Water flea (Daphnia magna)	32 mg/l, 48 hours Static test
Talc (CAS 14807-96-6)			
Aquatic			
Acute			
Fish	EC50	Zebra fish (Adult Brachydanio rerio)	> 100 g/l, 24 hours Static renewal test

Material name: LISKONUM TABLETS

SDS AUSTRALIA 4365

Components Species Test results

Titanium dioxide (CAS 13463-67-7)

Aquatic Acute

Crustacea EC50 Water flea (Daphnia magna) > 1000 mg/l, 48 hours Static test

Persistence and degradability

Biodegradability

Percent degradation (Aerobic biodegradation-inherent)

POVIDONE 30 0 %, 28 days Modified MITI test, Activated sludge

Bioaccumulative potential No data available.

Mobility in soil No data available for this product.

Mobility in generalNot available.Other adverse effectsNot available.

13. Disposal considerations

Disposal methodsCollect and reclaim or dispose in sealed containers at licensed waste disposal site. Do not

discharge into drains, water courses or onto the ground. Dispose in accordance with all applicable

regulations.

Residual waste Dispose of in accordance with local regulations. Empty containers or liners may retain some

product residues. This material and its container must be disposed of in a safe manner (see:

Disposal instructions). Avoid discharge into water courses or onto the ground.

Contaminated packaging Empty containers should be taken to an approved waste handling site for recycling or disposal.

Since emptied containers may retain product residue, follow label warnings even after container is

emptied.

14. Transport information

IATA

Not regulated as dangerous goods.

IMDG

Not regulated as dangerous goods.

Transport in bulk according to Not available.

Annex II of MARPOL 73/78 and

Annex II of MARPOL 73/78 and

the IBC Code

15. Regulatory information

Safety, health and environmental regulations

National regulations This Material Safety Data Sheet was prepared in accordance with the Australia National Code of

Practice for the Preparation of Material Safety Data Sheets (NOHSC: 2011.)

Australia Medicines & Poisons Appendix A

Poisons schedule number not allocated.

Australia Medicines & Poisons Appendix B

POVIDONE 30 (CAS 9003-39-8)

Low toxicity. Veterinary

Australia Medicines & Poisons Appendix C

Poisons schedule number not allocated.

Australia Medicines & Poisons Appendix D
Poisons schedule number not allocated.

Australia Medicines & Poisons Appendix E

tralia Medicines & Poisons Appendix E

Poisons schedule number not allocated. **Australia Medicines & Poisons Appendix F**

tralia Medicines & Poisons Appendix i

Poisons schedule number not allocated.

Australia Medicines & Poisons Appendix G

Poisons schedule number not allocated.

Australia Medicines & Poisons Appendix H

Poisons schedule number not allocated.

Material name: LISKONUM TABLETS
4365

^{*} Estimates for product may be based on additional component data not shown.

Australia Medicines & Poisons Appendix I

Poisons schedule number not allocated.

Australia Medicines & Poisons Appendix J

Poisons schedule number not allocated.

Australia Medicines & Poisons Appendix K

Poisons schedule number not allocated.

Australia Medicines & Poisons Schedule 2

Poisons schedule number not allocated.

Australia Medicines & Poisons Schedule 3

Poisons schedule number not allocated.

Australia Medicines & Poisons Schedule 4

Poisons schedule number not allocated.

Australia Medicines & Poisons Schedule 5

Poisons schedule number not allocated.

Australia Medicines & Poisons Schedule 6

Poisons schedule number not allocated.

Australia Medicines & Poisons Schedule 7

Poisons schedule number not allocated.

Australia Medicines & Poisons Schedule 8

Poisons schedule number not allocated.

Australia Medicines & Poisons Schedule 9

Poisons schedule number not allocated.

High Volume Industrial Chemicals (HVIC)

Talc (CAS 14807-96-6)

100000 - 999999 TONNES See the regulation for additional

information.

Titanium dioxide (CAS 13463-67-7)

100000 - $999999\ \mbox{TONNES}$ See the regulation for additional information.

Importation of Ozone Deleting Substances (Customs(Prohibited imports) Regulations 1956, Schedule 10)

Not listed

National Pollutant Inventory (NPI) substance reporting list

Not listed.

Prohibited Carcinogenic Substances

Not regulated.

Prohibited Substances (National Model Regulation for the control of Workplace Hazardous Substances, Schedule 2 NOHSC:1005 (1994) as amended)

Not listed.

Resricted Importation of Organochlorine Chemicals (Customs(Prohibited Imports) Regulations 1956, Schedule 9)

Not listed.

Restricted Carcinogenic Substances

Not regulated.

International regulations

Stockholm Convention

Not applicable.

Rotterdam Convention

Not applicable.

Kyoto protocol

Not applicable.

Montreal Protocol

Not applicable.

Basel Convention

Not applicable.

International Inventories

Country(s) or region	Inventory name	On inventory (yes/no)*
Australia	Australian Inventory of Chemical Substances (AICS)	No
Canada	Domestic Substances List (DSL)	No
Canada	Non-Domestic Substances List (NDSL)	No

Material name: LISKONUM TABLETS

SDS AUSTRALIA

Country(s) or region	Inventory name	On inventory (yes/no)*
China	Inventory of Existing Chemical Substances in China (IECSC)	No
Europe	European Inventory of Existing Commercial Chemical Substances (EINECS)	No
Europe	European List of Notified Chemical Substances (ELINCS)	No
Japan	Inventory of Existing and New Chemical Substances (ENCS)	No
Korea	Existing Chemicals List (ECL)	No
New Zealand	New Zealand Inventory	No
Philippines	Philippine Inventory of Chemicals and Chemical Substances (PICCS)	No
United States & Puerto Rico	Toxic Substances Control Act (TSCA) Inventory	No

^{*}A "Yes" indicates that all components of this product comply with the inventory requirements administered by the governing country(s) A "No" indicates that one or more components of the product are not listed or exempt from listing on the inventory administered by the governing country(s).

16. Other information

Issue date04-November-2014Revision date04-November-2014

References GSK Hazard Determination

Disclaimer The information and recommendations in this safety data sheet are, to the best of our knowledge,

accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and

the suitability of the material or product for any particular purpose.

Revision Information Product and Company Identification: Product and Company Identification

Composition / Information on Ingredients: Undisclosed Ingredient Statement

Physical & Chemical Properties: Toxicological Information: Ecological information:

Transport Information: Material Transportation Information

Regulatory Information: Risk Phrases - Class.

GHS: Classification

Material name: LISKONUM TABLETS SDS AUSTRALIA